STAT Plus: Blueprint Medicines wins U.S. approval for genetically targeted lung cancer drug
ANDY WONG/AP
The FDA approved a new drug from Blueprint Medicines for patients with lung cancer driven by a rare gene mutation.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario